Product Name
Reserpine hydrochloride
Description
Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2).
Structural Formula
Reserpine hydrochloride
Solubility
DMSO : 50 mg/mL(77.50 mM;Need ultrasonic) H2O : 1 mg/mL(1.55 mM;ultrasonic and warming and heat to 80°C)
Source
Plants >Apocynaceae > Rauvolfia verticillata(Lour.) Baill.
Storage
4℃, sealed storage, away from moisture and light
Shipping
Room temperature in continental US; may vary elsewhere.
SMILES
O=C([C@H]([C@@H](OC)[C@H](OC(C1=CC(OC)=C(OC)C(OC)=C1)=O)C[C@]2([H])CN3CC4)[C@@]2([H])C[C@]3([H])C5=C4C(C=CC(OC)=C6)=C6N5)OC.Cl
In Vivo
Withdrawal (48 h) from chronic (14-day) but not acute Reserpine hydrochloride administration in a dose of 0.2 mg/kg i.p. produces a significant reduction of the immobility time (F2,18=3.68, p<0.05), but increases the climbing time (F2,18=4.48, p<0.02), and does not change the swimming time (F2,18=1.78; NS) in the forced swim test (FST) in rats. Reserpine hydrochloride at a dose of 5 mg/kg body weight produces significant increase in the urinary excretion profile of vanillylmandelic acid (VMA) compare to control animals. The amount of 5-hydroxyindoleacetic acid (5-HIAA) excreted in animals treated with Reserpine is found to be more than in the control. Dose dependent hypotension is observed with Reserpine hydrochloride. Reserpine hydrochloride at doses of 0.5, 1, 5, 10 and 15 μg/kg produce significant (p<0.01) reduction in blood pressure compare to control.
In Vitro
Reserpine hydrochloride is an inhibitor of the vesicular monoamine transporter 2 (VMAT2). Reserpine hydrochloride displays a significant on the density of dopamine D1 receptors (F2,12=8.81, p<0.01) in the rat striatum. The affinity (Kd) for the dopamine D1 and D2 receptors during withdrawal from acute and chronic administration of reserpine is not change.
Datasheet 
